Navigation Links
Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
Date:8/11/2009

l stem cells collected from women across mainland China, the company expects to offer other products and services associated with stem cell therapy; gene testing and disease diagnosis (i.e. gene chips; high throughput sequencings and standard molecular technologies). SEB expects to receive funding from private agencies and the government for stem cell research.

In recent years, China has significantly increased its efforts in the field of stem cell research and practice. Currently, scientific research in the country primarily utilizes bone marrow and embryonic stem cells. Clinical applications of stem cells to treat conditions such as acute heart failure, acute liver failure and lower limb ischemia have been reported by many hospitals. A developing country with the largest population in the world, China's estimated total population is 1.3 billion of which women account for about half. SEB believes that the future market opportunity for the C'elle service in China is potentially significant.

"Stem cell research and development is well-recognized and fast-emerging in China. SEB believes that the innovative proprietary technology of C'elle may provide women with the novel opportunity to collect and cryopreserve their own stem cells that have demonstrated considerable potential to be used in future therapies and are easily harvest from a non-controversial source," stated Dr. Charlie Xiang, CEO of S-Evans Biosciences. "Through SEB's expansive educational, scientific and medical affiliations, we anticipate that there may possibly be enormous potential opportunity to successfully market the compelling and highly differentiated quality service of C'elle. We are also eager to explore prospective opportunities with Cryo-Cell to collaborate on research and development of future potential stem cell therapies that may utilize this breakthrough technology."

"We are particularly interested in supporting research on stem c
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cryo-Cell International, Inc. Reports First Quarter 2009 Results
2. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
5. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
6. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
7. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
8. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
9. WuXi PharmaTech Announces Second-Quarter 2009 Results
10. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... The National Necrotizing Fasciitis Foundation ... by doctors at Vanderbilt University Hospital in ... and Dr. John Crew , director of the ... Center in Daly City, CA. ... pioneered by Dr. Crew, that had previously saved the ...
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended June ... in Canadian dollars and presented under International Financial ... activities with respect to our Oral Amp B ... contract manufacturer," said Andrew Rae , President ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Reportlinker.com announces that a new market research ... Established and Emerging Biotech Clusters ... There has been widespread interest ... companies and related organizations. It is important ...
... Keryx Biopharmaceuticals (Nasdaq: KERX ) today ... component of its Phase 3 registration program of Zerenex™, ... of elevated serum phosphorus levels, or hyperphosphatemia, in patients ... Phase 3 registration program, which is being conducted pursuant ...
... The ALS Therapy Development Institute (ALS TDI) and ... their current research collaboration agreement to test additional ... stop the progression of Amyotrophic Lateral Sclerosis (ALS, ... collaboration is based on encouraging results from early-stage ...
Cached Biology Technology:Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 2ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 3
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... that one of the cell's largest families of signaling ... development of nerve cells, also controls nerve cells' ability ... memory. These findings, the first to link these molecular ... the May issue of Nature Cell Biology, published in ...
... of BioModels, the world's first database of annotated ... collaboration led by the European Bioinformatics Institute (UK) ... develops open-source standards to describe biological systems. Other ... Systems Biology Institute (Japan) and Stellenbosch University (South ...
... of medical scientists has made an important advance in ... cancer in the industrialized world. Professor Jeremy R. Jass, ... at McGill University in Montreal, and colleagues in Australia ... cancer can be inherited. The new syndrome is characterized ...
Cached Biology News:Structure-building cell signals also may influence learning and memory 2Structure-building cell signals also may influence learning and memory 3A new way to share models of biological systems 2Important discovery about second most fatal cancer 2
... For separation and ... Efficient separation of nuclei from ... in sample complexity, greatly facilitating ... Subfractionation of nucleic acid binding ...
... of Eagle's medium have been ... The most widely used modification ... is a modification of Minimum ... contains a higher concentration of ...
... The EpiTect Bisulfite Kit enables ... uracils in less than 6 hours. ... innovative protection against DNA degradation and ... to guarantee fast and reliable results ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
Biology Products: